5 High Growth Healthcare Stocks to Buy

2. Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Number of Hedge Fund Holders: 44

California-based Neurocrine Biosciences, Inc. (NASDAQ:NBIX) ranks 2nd in our list of 12 high growth healthcare stocks to buy. Neurocrine Biosciences, Inc. (NASDAQ:NBIX) focuses on neurological diseases. In the fourth quarter of 2022 Neurocrine Biosciences, Inc. (NASDAQ:NBIX)’s revenue jumped about 32% on a YoY basis to reach $412 million, beating estimates by $3.04 million.

Neurocrine Biosciences, Inc. (NASDAQ:NBIX)’s sales for INGREZZA during fiscal 2022 came in at $1.43 billion.

Earlier this month, Neurocrine Biosciences, Inc. (NASDAQ:NBIX) jumped after Morgan Stanley upgraded NBIX to Overweight from Equal Weight. The firm noted FDA’s approval for Ingrezza for Huntington’s disease chorea.

44 of the 920 hedge funds tracked by Insider Monkey had stakes in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) at the end of the third quarter of 2022. The total value of these hedge funds’ stakes was about $1.3 billion. The biggest stakeholder of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) during this period was David Witzke and Michael Gregory’s Avidity Partners Management which owned a $197.1 million stake in the company.